Israel ischemic heart disease (IHD) Drugs Market, Disease Class (Angina Pectoris, Myocardial Infarction), By Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, ACE Inhibitors, ARBs, Vasodilators, Antithrombotic Agents), By Regio

Israel ischemic heart disease (IHD) Drugs Market, Disease Class (Angina Pectoris, Myocardial Infarction), By Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, ACE Inhibitors, ARBs, Vasodilators, Antithrombotic Agents), By Region, Competition, Forecast & Opportunities, 2028F

Israel ischemic heart disease (IHD) Drugs Market is expected to grow at an impressive rate during the forecast period, 2024-2028. The major factors include the rising prevalence of chronic diseases such as cardiovascular diseases, cancer, and diabetes and the growing adoption of technological advancement. The increasing awareness of the masses toward interventional medical procedures along with extensive utilization of anti-anginal medications for the treatment of ischemic heart diseases is one of the key factors driving the growth of the Israel ischemic heart diseases market. Additionally, the unhealthy lifestyle and lack of physical activity are projected to promote the growth of the Israel ischemic heart disease (IHD) drugs market during the forecast period. According to World Health Organization 2020, diabetes mellitus deaths in Israel reached to around 1,913 or 5.44% of total deaths. The age adjusted death rate is 13.96 per 100,000 of population.

Ischemic heart disease is a condition that occurs when the blood supply to the heart is reduced or blocked, leading to damage of heart muscle tissue. This is mostly caused by atherosclerosis, a buildup of plaque in the arteries that supply blood to the heart, which can narrow or block these arteries. The most common symptom of ischemic heart disease is angina in which the heart does not get proper oxygen. Risk factors for ischemic heart disease include age, smoking, high blood pressure, high cholesterol, diabetes, family history, and a sedentary lifestyle.

The rise in awareness related to complications associated with heart disease is a major factor that fuels the growth of the Israel ischemic heart disease (IHD) drugs market. Moreover, the increase in geriatric population and sedentary lifestyle boost the growth of the market. However, high cost of drugs, alternative therapies, and change in lifestyle are anticipated to hinder the growth of the Israel ischemic heart diseases market. Conversely, the rise in healthcare infrastructure is expected to offer lucrative opportunities to the market players during the forecast period.

Rising Prevalence of Ischemic Heart Disease

The increasing prevalence of ischemic heart disease drugs in Israel is driven by a combination of factors. These include the high prevalence of heart issues in the country, the aging population, and the growing demand for effective treatments. In addition, the Israeli government has launched several initiatives to improve the prevention and management of cardiovascular diseases, including ischemic heart disease. For instance, according to the World Health Organization (WHO), ischemic heart disease accounted for approximately 8.9 million deaths in 2019. The increasing prevalence of risk factors such as obesity, diabetes, and high blood pressure has contributed to the rising incidence of ischemic heart disease, which, in turn, drives the demand for drugs to treat and manage the condition, thereby propelling the growth of the Israel ischemic heart disease (IHD) drugs market . For instance, according to the research articles, around half (49%) of the patients with heart failure had ischemic heart disease, 44% had irregular heart rhythm (atrial fibrillation), and 34.5% had diabetes.

Many Israelis have adopted healthier lifestyles, including increased physical activity and healthier diets, which can help prevent and manage cardiovascular disease. However, lifestyle changes may not be enough to prevent or manage the condition in all cases, and drugs may be necessary to control symptoms and prevent complications. Moreover, the increasing prevalence of ischemic heart disease drugs in Israel is driven by a combination of factors, including the high prevalence of the condition, the aging population, advances in drug development and technology, government initiatives, and lifestyle changes. Thus, with the increasing demand for effective drugs to treat and manage ischemic heart diseases, the growth of the Israel ischemic heart disease (IHD) drugs market is projected to grow during the forecast period.

Development of Healthcare Infrastructure

Israel is known for its innovative and advanced healthcare infrastructure, and the country has a thriving pharmaceutical industry. Advances in drug development and technology have led to the introduction of new and improved drugs to treat ischemic heart disease, which is subjected to propel the growth of the Israel ischemic heart disease (IHD) drugs market . Several other factors that will boost the growth of the Israel ischemic heart disease (IHD) drugs market include growing initiatives by private and government organizations and rising awareness for drugs with its maximum efficacy to treat ischemic heart diseases. A few organizations dealing with the products of heart diseases drugs have taken initiatives to conduct a camp and checked the blood pressure and made them aware of various aspects of high blood pressure. Such factors have driven the growth of the Israel ischemic heart disease (IHD) drugs market . A major Israel’s healthcare authority is the National Health Insurance Law, which allows every resident to choose 1 of 4 health plans regardless of age, pre-existing conditions, or health status. The different quality measures of essential cardiovascular therapeutics are monitored by health maintenance organizations and by the Medical Quality Division of the Ministry of Health in Israel. The government had developed a society called Israel Heart Society which is a member of the European Society of Cardiology to promote the prevention and treatment of heart diseases, encourage professional and scientific knowledge and education, increase the awareness of cardiovascular health, and advocate for cardiovascular therapeutic. The Israel Heart Society conducts national surveys to describe cardiac health status and trends in therapeutic management. The most established survey is the Acute Coronary Syndrome Israeli Survey. All these efforts across the country are responsible for propelling the growth of Israel ischemic heart diseases drugs market.

Public health campaigns have also played a role in increasing awareness of the health risks associated with ischemic heart disease in Israel. These campaigns aim to educate the public about the importance of healthy lifestyle choices, such as diet and exercise. They also encourage people to get their blood pressure checked regularly and to seek medical treatment if their blood pressure is high. To increase awareness of ischemic issues in Israel, a few outreach programs, educational efforts, and public health campaigns have been taken forward. The main objectives of these programs are to inform the public about the causes of ischemic heart diseases, the value of healthy heart, and the advantages of treatments and formulation of drugs. The Israel’s Ministry of Health has also taken steps to address the growing prevalence of cardiovascular diseases by implementing national guidelines for the prevention, diagnosis, and treatment of the condition. These initiatives aim to increase awareness, improve access to healthcare, and support research and development in the field of ischemic heart stroke, which, in turn, will drive the growth of the Israel ischemic heart disease (IHD) drugs market during the forecast period.

Market Segmentation

The Israel ischemic heart disease (IHD) drugs market can be segmented by disease class, drug class, and region. By disease class, the market can be segmented into angina pectoris, myocardial infarction. Based on drug class, the market can be segmented into anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, ACE inhibitors, ARBs, vasodilators, and antithrombotic agents.

Market Players

Pfizer Pharmaceuticals Israel Ltd, MERCK SERONO LTD., GlaxoSmithKline Israel Ltd, Bayer-Israel, Novartis Pharma Israel Ltd, Sanofi-Aventis Israel Ltd, Eli Lilly Israel, Actelion Pharmaceuticals Israel Ltd, Bristol-Myers Squibb Israel Ltd, and Roche Pharmaceuticals (Israel) Ltd.. are some of the leading companies operating in the Israel ischemic heart disease (IHD) Drugs Market.

Report Scope:

In this report, the Israel ischemic heart disease (IHD) Drugs Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Israel ischemic heart disease (IHD) Drugs Market, By Disease Class
• Angina Pectoris
• Myocardial Infarction
• Israel ischemic heart disease (IHD) Drugs Market, By Drug Class
• Anti-Dyslipidemic Drugs
• Calcium Channel Blockers
• Beta-Blockers
• ACE Inhibitors
• ARBs
• Vasodilators
• Antithrombotic Agents
• Israel ischemic heart disease (IHD) Drugs Market, By Region:
• The Mediterranean coastal plain
• The Central Hills
• The Jordan Rift Valley
• The Negev Desert

Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Israel ischemic heart disease (IHD) drugs market.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order. Single User license will be delivered in PDF format without printing rights